
 
													 
									 
															 
															Year
 
															DEALS // DEV.
 
															Country
 
															 
															Therapeutic Area
 
															Study Phase
 
															Deal Type
 
															Product Type
 
															Dosage Form
 
															Lead Product
 
															Target

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $812.0 million
Deal Type : Collaboration
Novo Nordisk Inks $812M Deep Apple Deal to Pursue Obesity Target
Details : The collaboration aims to discover, develop, and commercialize oral small molecule therapeutics directed at a novel non-incretin GPCR target for cardiometabolic diseases, including obesity.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
June 11, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery Platform
Sponsor : Novo Nordisk
Deal Size : $812.0 million
Deal Type : Collaboration

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Discovery
Sponsor : Apple Tree Partners
Deal Size : $52.0 million
Deal Type : Series A Financing
Details : The net proceeds will be used for advancing multiple novel small molecule therapeutics focused on GPCR modulators, a proven target class with applications in metabolic disorders, inflammation, immunology, and endocrine diseases.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 14, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Discovery
Sponsor : Apple Tree Partners
Deal Size : $52.0 million
Deal Type : Series A Financing

 Reset All
Reset All